T. Bhatt

Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors.

K. Hess, F. Meric-Bernstam, F. Janku, 2016 .

Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study

K. Hess, F. Meric-Bernstam, A. Ryan, 2021, ESMO open.

Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.

K. Hess, D. Carbone, R. Salgia, 2018 .